申请人:PRINCIPIA BIOPHARMA INC.
公开号:US20160045503A1
公开(公告)日:2016-02-18
Oral pharmaceutical formulations comprising reversible covalent compounds having a Michael acceptor moiety, a process of their production and use of these formulations for the treatment of diseases treatable by such compounds such as cancer and autoimmune diseases.
口服药物制剂包括具有Michael受体基团的可逆共价化合物,其生产过程以及利用这些制剂治疗可通过此类化合物治疗的疾病,例如癌症和自身免疫性疾病。